The TKI bezuclastinib plus standard-of-care sunitinib may become the new second-line standard treatment for patients with gastrointestinal stromal tumor that has progressed on imatinib.
Neeta Somaiah, MD, discusses enrollment criteria for the phase 3 Peak trial in patients with gastrointestinal stromal tumor and the advantages of this trial’s design.
The combination of bezuclastinib and sunitinib had a tolerable safety profile and demonstrated early signals of clinical activity in patients with gastrointestinal stromal tumor.
Drs Jones and Somaiah discuss unmet needs in GIST that the Peak trial seeks to answer; the advantages of the methods and design of this trial; and how the tolerable safety profile of bezuclastinib plus sunitinib supports further research with this combination.
significant here is manipulating courts. what s really significant here is that manipulating courts. what s really significant here is that in - manipulating courts. what s really significant here is that in no - manipulating courts. what s really significant here is that in no way. significant here is that in no way trump significant here is that in no way trump would significant here is that in no way trump would be significant here is that in no way trump would be ok significant here is that in no way trump would be ok with - significant here is that in no way trump would be ok with being l significant here is that in no way. trump would be ok with being on trial having trump would be ok with being on trial having an trump would be ok with being on trial having an extended - trump would be ok with being on trial having an extended trial i trial having an extended trial during trial having an extended trial during his trial having an extended trial during his peak